Solid Biosciences Inc.
SLDB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | 1.80 | 0.04 |
| FCF Yield | -61.66% | -78.38% | -220.53% | -42.30% |
| EV / EBITDA | -0.88 | -0.80 | 0.84 | -1.01 |
| Quality | ||||
| ROIC | -78.89% | -67.27% | -33.39% | -34.09% |
| Gross Margin | 0.00% | 0.00% | 70.25% | 78.24% |
| Cash Conversion Ratio | 0.80 | 0.98 | 1.14 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | – |
| Free Cash Flow Growth | -5.19% | 5.24% | -27.77% | -37.47% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 0.51 | 1.31 | 1.69 |
| Interest Coverage | -381.55 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.49 |
| Cash Conversion Cycle | -629.94 | -287.36 | -490.81 | 194.07 |